

1 **Clinical, imaging, serological, and histopathological features of pulmonary post-acute
2 sequelae after mild COVID-19 (PASC)**

3 **Gagiannis D¹, Hackenbroch C^{2,3}, Czech A⁴, Lindner A¹, Maag N⁴, Bloch W⁵, Zech F⁶, Kirchhoff F⁶, Djudjaj S⁷, von
4 Stillfried S⁷, Bülow R⁷, Boor P^{7*}, Steinestel K^{4*}**

5 ¹Department of Pulmonology, Bundeswehrkrankenhaus Ulm, 89081 Ulm, Oberer Eselsberg 40, Germany;

6 ²Department of Radiology, Bundeswehrkrankenhaus Ulm, 89081 Ulm, Oberer Eselsberg 40, Germany;

7 ³Department of Radiology, Ulm University Medical Center, 89081 Ulm, Albert-Einstein-Allee 23, Germany

8 ⁴Institute of Pathology and Molecular Pathology, Bundeswehrkrankenhaus Ulm, 89081 Ulm, Oberer Eselsberg

9 40, Germany; ⁵Department of Molecular and Cellular Sport Medicine, German Sport University Cologne, 50933

10 Cologne, Am Sportpark Müngersdorf 6, Germany; ⁶Institute of Molecular Virology, Ulm University Medical

11 Center, 89081 Ulm, Meyerhofstr. 1, Germany, ⁷Institute of Pathology, RWTH Aachen University Hospital, 52074

12 Aachen, Pauwelsstrasse 30, Germany.

13 *these authors contributed equally

14 **Corresponding author:**

15 **Konrad Steinestel, MD PhD**

16 Institute of Pathology and Molecular Pathology

17 Bundeswehrkrankenhaus Ulm

18 Oberer Eselsberg 40

19 89081 Ulm, Germany

20 T: 0049 731 1710 2400

21 F: 0049 731 1710 2403

22 konradsteinestel@bundeswehr.org

23 **Funding:** This work was in part supported by the German Registry of COVID-19 Autopsies
24 (www.DeRegCOVID.ukaachen.de), funded by the Federal Ministry of Health (ZMVI1-2520COR201), and the
25 Federal Ministry of Education and Research within the framework of the network of university medicine
26 (NATON, No. 01KX2121). FZ and FK are supported by CRC 1279.

27 **Declaration of interest:** DG and KS were speakers for Boehringer-Ingelheim. All other authors declare no
28 conflict of interest.

29 **Key points**

- 30 • Dyspnea on exertion is the leading clinical manifestation of PASC in the lung
- 31 • a minority of pts have significantly impaired lung function (FVC/TLC≤80% or DLCO≤70%) in
32 spiroergometry and/or radiologic abnormalities, oxygen pulse seems to normalize over time
 - 33 ○ 16% and 42.9% of pts have FEV1 and MEF50 ≤80% and 35.3% have LAV>5% of lung area, in
34 line with airflow obstruction due to bronchiolitis
- 35 • Residual virus was not detectable in the lung tissue of all but one PASC patient (2%)
- 36 • Histologically, PASC may manifest as T cell-mediated bronchiolitis, OP and fibrinous alveolitis
- 37 • There is evidence of fibrotic remodeling (ultrastructural interstitial fibrosis, pro-fibrotic macrophage
38 subpopulation, pro-fibrotic cytokine IL-1β in BAL) but this did not correlate with the degree of T cell
39 infiltrate/bronchiolitis

40 **ABSTRACT**

41 Background: A significant proportion of patients experience prolonged pulmonary, cardiocirculatory or
42 neuropsychiatric symptoms after Coronavirus disease 2019 (COVID-19), termed post-acute sequelae of COVID
43 (PASC). Lung manifestations of PASC include cough, dyspnea on exertion and persistent radiologic
44 abnormalities and have been linked to viral persistence, ongoing inflammation and immune dysregulation. So
45 far, there is limited data on lung histopathology and tissue-based immune cell subtyping in PASC.

46

47 Methods: 51 unvaccinated patients (median age, 40 years; 43% female) with a median of 17 weeks (range, 2-55
48 weeks) after mild SARS-CoV-2 infection (without hospitalization) underwent full clinical evaluation including
49 high-resolution computed tomography (HR-CT) and transbronchial biopsy. We used RT-PCR/FISH and
50 immunohistochemistry (nucleocapsid/spike/CD3/CD4/CD8) for residual SARS-CoV-2 detection and T
51 lymphocyte subtyping, respectively. We assessed interstitial fibrosis and macrophage profiles by transmission
52 electron microscopy (TEM) and immunofluorescence multiplex staining, while cytokine profiling in broncho-
53 alveolar lavage (BAL) fluid was performed by legendplex immunoassay.

54

55 Results: Dyspnea on exertion was the leading symptom of pulmonary PASC in our cohort. In 16% and 42.9% of
56 patients, FEV1 and MEF50 were ≤80% and 35.3% showed low attenuation volume (LAV) in >5% of lung area, in
57 line with airflow obstruction. There was a significant correlation between oxygen pulse and time since COVID
58 ($p=0.009$). Histopathologically, PASC manifested as organizing pneumonia (OP), fibrinous alveolitis and
59 increased CD4+ T cell infiltrate predominantly around airways (bronchiolitis), while the residual virus
60 components were detectable in only a single PASC patient (2%). T cell infiltrates around small airways were
61 inversely correlated with time since COVID, however, this trend failed to reach statistical significance. We
62 identified discrete interstitial fibrosis and a pro-fibrotic macrophage subtype (CD68/CD163/S100A9) as well as
63 significantly elevated interleukin 1 β in BAL fluid from PASC patients ($p=0.01$), but H-scores for fibrotic
64 macrophage population did not correlate with severity of clinical symptoms or T cell infiltration.

65

66 Interpretation: We show decreased FEV1/MEF50 and increased LAV in line with obstructive lung disease due to
67 CD4+ T cell-predominant bronchiolitis as well as evidence of pro-fibrotic signaling in a subset of unvaccinated
68 PASC patients. Since our results point towards self-limiting inflammation of small airways without detectable
69 viral reservoirs, it remains unclear whether pulmonary symptoms in PASC are SARS-CoV-2-specific or represent
70 a general response to viral infection. Still, evidence of pro-fibrotic signaling should warrant clinical follow-up
71 and further research into possible long-time fibrotic remodeling in PASC patients.

72

73 **RUNNING TITLE**

74 Pathology of pulmonary post-acute sequelae of COVID-19

75 **KEYWORDS**

76 COVID-19, SARS-CoV-2, PASC, lung pathology, longCOVID, postCOVID, lung fibrosis

77 **INTRODUCTION**

78 Following SARS-CoV-2 infection, a subgroup of patients develop lasting symptoms, termed post-acute sequelae
79 of COVID-19 (PASC). The burden of PASC is associated with the severity of the initial disease and lies between
80 4% and 15% at 6 to 8 months among non-hospitalized patients[1-3]. Lung manifestations of PASC include
81 shortness of breath, chest pain and imaging abnormalities such as ground glass opacities (GGO) and subpleural
82 bands [4]. Concerning pulmonary function tests, a systematic review and meta-analysis reported altered
83 diffusion lung capacity for carbon monoxide (DLCO), and restrictive and obstructive patterns in PASC patients,
84 but the test results did not correlate with the subjective severity of symptoms in another study [5,6].
85 Concerning histopathology, one study did not find distinct post-acute histopathologic changes in lung tissue of
86 elective lung resection specimens from patients after mild and moderate COVID-19, however, these patients
87 did not show PASC symptoms [7]. Another case study reported extensive interstitial fibrosis in a lung explant
88 from a 62-year-old man 12 weeks after recovering from mild COVID-19 [8]. While it is clear that the long-term
89 outcome in patients after severe COVID-19 (SARS-CoV-2-associated acute respiratory distress syndrome, ARDS,
90 and/or who underwent mechanical ventilation) might be explained by widespread lung damage, the
91 pathophysiology of pulmonary sequelae in mild cases of COVID-19 is unclear. It has been proposed that
92 impaired lung function might be associated with dysregulated respiratory CD8+ T cell responses or damage to
93 the pulmonary vasculature after acute COVID-19 [9,10]. Furthermore, presence of circulating antinuclear
94 autoantibodies (ANA) have been shown to predict PASC in COVID-19 survivors [11]. This is of interest given the
95 association between the presence of autoantibodies (ANA/ENA) and the severe course of acute COVID-19,
96 which we have previously described [12]. Another hypothesis for the pathogenesis of PASC is based on a
97 possible persistence of SARS-CoV-2 or viral particles/mRNA in tissue, driving chronic inflammation [13].
98 Verification of each of these hypotheses is hampered by the lack of data on tissue samples from PASC patients
99 in most published studies. The present multidisciplinary study aimed to characterize clinical, imaging,
100 serological and histopathological features in a consecutive cohort of PASC patients from our postCOVID
101 outpatient clinic.

102 **METHODS**

103 **Patients and diagnostic work-up**

104 We included n=66 patients with a history of RT-PCR-confirmed SARS-CoV-2 infection and persistent pulmonary
105 symptoms in the present study. All patients were unvaccinated at the time of SARS-CoV-2 infection (before
106 vaccine roll-out) and had a mild clinical course (without hospitalization). The baseline diagnostic workup
107 included clinical history including current and previous medication and allergies, physical examination and
108 spiroergometry. ANA/ANCA/ENA screening was performed as previously described [12]. After multidisciplinary
109 discussion, bronchoscopy with transbronchial biopsy for the assessment of possible PASC-ILD was performed in
110 n=51 patients who formed the definite cohort. Patients have given written informed consent to routine
111 diagnostic procedures (serology, bronchoscopy, imaging) as well as to the scientific use of data and tissue
112 samples in the present study. This project was approved by the local ethics committee of the University of Ulm
113 (ref. no. 129-20) and conducted in accordance with the Declaration of Helsinki.

115 **Imaging**

116 Imaging of the lung was performed on a 3rd generation DECT Scanner (Siemens Somatom Force, Siemens
117 Healthineers, Forchheim, Germany). A non-contrast multislice spiral CT in full dose technique (Qual. Ref. kV: Sn
118 100, Qual. Ref. mAs: 600, ref. CTDI 1.06 mGy) with a collimation of 192 x 0.6 mm and using a tin prefilter at 100
119 resp. 150 kV was obtained. Rotation time 0.25 sec, scan time 1.25 sec. Examination was performed in
120 inspiration. Reconstruction in bone, soft tissue and lung window. The subsequent automated segmentation
121 and evaluation of the lung volumes as well as the determination of overinflated or fibrotically
122 altered/attenuated lung areas was carried out with the manufacturer-specific evaluation software "syngo.via",
123 version VB 40 (Siemens Healthineers, Forchheim, Germany) using the software "CT Pulmo 3D", with a
124 reconstruction set of the acquired CT scan with the following specifications: Slice thickness 0.75 mm, increment
125 0.5 mm, reconstruction with a medium soft kernel Br 40, iterative reconstruction: Admire stage 3. A threshold
126 value of minimum -950 HU (low attenuation value, LAV) and maximum -200 HU (high attenuation value, HAV)
127 was defined as the limits of regularly ventilated lung areas. Values below LAV were considered overinflated
128 areas, values above HAV were considered attenuated lung areas.

129 **Histology and SARS-CoV-2 detection**

130 Lung tissue specimens were obtained as transbronchial biopsies and stained with haematoxylin-eosin (HE),
131 Elastica-van-Gieson (EvG) and Masson-Goldner (MG). Slides were reviewed with special emphasis on possible
132 post-viral change (alveolitis, peribronchiolitis, airway smooth muscle hypertrophy, goblet cell hyperplasia,
133 airway squamous epithelial metaplasia, and fibrosis)[14]. We performed immunohistochemistry for Spike and
134 Nucleocapsid proteins of SARS-CoV-2 using the following antibodies: anti-SARS-CoV-2 spike antibody, clone
135 1A9, mouse monoclonal, 1:400 (GeneTex, Irvine, CA, USA); anti-SARS-CoV-2 nucleocapsid antibody, rabbit
136 monoclonal, 1:20000 (SinoBiological, Beijing, China). Autopsy-derived tissue samples from deceased COVID-19
137 patients (**Fig. 2 B**, upper panel) served as positive controls [15]. For SARS-CoV-2 fluorescence in situ
138 hybridization (FISH), paraformaldehyde-fixed, paraffin-embedded 1µm sections of transbronchial biopsies
139 (TBBs) and lung autopsy material (positive controls) were deparaffinized followed by dehydration with 100%
140 ethanol. FISH was performed with the RNAscope® Multiplex Fluorescent Reagent Kit v2 assay (Advanced Cell
141 Diagnostics, Inc.) according to the manufacturer's instruction. Briefly, a heat-induced target retrieval
142 step followed by protease was performed. Afterwards sections were incubated with the following RNAscope®
143 Probe -V-nCoV2019-S (#848561-C1), -V-nCoV2019-S-sense (#845701-C1), -Hs-ACE2-C2 (#848151-C2) and -Hs-
144 TMPRSS2-C2 (#470341-C2). After the amplifier steps, the fluorophores OpalTM 570 and 650 (PerkinElmer Life
145 and Analytical Sciences) were applied to the tissues incubated with C1 and C2 probes, respectively.
146 Finally, nuclei were stained with DAPI and the slides were mounted with ProLongTM Gold antifade
147 reagent (Invitrogen). Sections were analyzed with Zeiss Axio Imager 2 and image analysis software (ZEN 3.0
148 blue edition). SARS-CoV-2 RNA was extracted using Maxwell® 16 FFPE Plus Tissue LEV DNA Purification KIT
149 (Promega) on Maxwell® 16 IVD Instrument (Promega). Using TaqMan® 2019-nCoV kit (ThermoFisher), the
150 detection of SARS-CoV-2 E-gene was performed according to the manufacturer's instructions.

152 **Electron microscopy**

153 Lung tissue was immersion-fixed with 4% paraformaldehyde in 0.1M PBS, pH 7.4. After several washing steps in
154 0.1M PBS, tissue was osmicated with 1% OsO₄ in 0.1 M cacodylate and dehydrated in increasing ethanol
155 concentrations. Epon infiltration and flat embedding were performed following standard procedures.
156 Methylene blue was used to stain semithin sections of 0.5 µm. Seventy to ninety-nanometer-thick sections
157 were cut with an Ultracut UCT ultramicrotome (Fa. Reichert) and stained with 1% aqueous uranyl acetate and
158 lead citrate. Samples were studied with a Zeiss EM 109 electron microscope (Fa. Zeiss) coupled to a TRS USB
159 (2048x2048, v.596.0/466.0) camera system with ImageSP ver.1.2.6.11 (x64) software.

160 **Staining Macrophage Panel**

161 Slides underwent antigen retrieval in citrate buffer (EnVision FLEX TARGET RETRIEVAL SOLUTION LOW pH, from
162 Agilent: K8005) using the pT-Link module (Agilent, Santa Clara, USA). After fixation in 4% formalin for 10 min,
163 slides were washed and blocking was performed with H₂O₂ (DAKO REAL PEROXIDASE-BLOCKING SOLUTION,
164 Agilent, Santa Clara, USA: S2023) followed by 30 min incubation with antibody diluent (DAKO REAL ANTIBODY
165 DILUENT, Agilent, Santa Clara, USA: S2022). Immunofluorescence multiplex staining was performed with Opal
166 7-Color Manual IHC Kit (AKOYA Biosciences, Menlo-Park, USA: NEL811001KT). The slides were incubated for 1
167 hour with primary antibodies: CD68 (Agilent, Santa Clara, USA: M0876), CD163 (Cell Marque: 163M-17),
168 S100A9 (Abcam: ab63818) and CD16 (Santa Cruz Biotechnology, Dallas, USA: DJ130c), followed by incubation
169 with EnVision FLEX HRP (Agilent, Santa Clara: DM802) and visualized with Opal 690 TSA Plus, using Opal 650
170 TSA Plus, Opal 620 TSA Plus, and Opal 570 TSA Plus, respectively (all from AKOYA Biosciences, Marlborough,
171 USA). The nuclei were counterstained using Spectral DAPI (AKOYA Biosciences, Marlborough, USA).

172 **Macrophage phenotyping**

173 We scanned twelve regions of interest of lung tissue to multispectral images (MSI) per sample using the 40x
174 objective, corresponding to a tissue area of 334x250 µm² each. Scanning was performed using the VECTRA
175 automated quantitative pathology imaging system (Perkin Elmer, Waltham, USA). After deploying automated
176 cell detection using the InForm Software (Perkin Elmer, Waltham, USA), we trained an in-built cell phenotyping
177 algorithm to detect CD16+, CD16/CD163+, CD68+ and CD68+/CD163+ cells, as well as a final cell type
178 containing all other cells. Additionally, we assessed S100A9-Expression in the detected and classified cells
179 automatically in four bins (0-3) and calculated and H-Score of S100A9-Expression. After training all samples
180 were analyzed in one batch using the finale algorithm. Measurement outputs of the InForm Software were
181 analyzed in R version 4.0.3 using the phenoptr (v0.3.2) and phenoptrReports (v0.3.3) packages.

182 **BAL analysis and legendplex immunoassay**

183 The Legendplex ELISA was performed according to the manufacturer's instructions. In brief, 25 µl of the
184 collected BAL was centrifuged (4000 rpm, 5 min) and incubated for 2 h at room temperature with antibody-
185 coated beads, followed by washing and incubation with the detection antibodies. After incubation with the
186 staining reagent, the beads were analyzed in a high-throughput sampler via flow cytometry (FACSCanto II, BD

187 Biosciences). Absolute quantification was performed using a standard and the Bio-legends Legendplex v8.0
188 software.

189 **Statistical Methods**

190 Descriptive statistical methods were used to summarize the data. Medians and interquartile ranges were used
191 to announce results. Absolute numbers and percentages were employed to represent categorial variables.
192 Student's t-test/ANOVA with multiple comparison post-test was used for the comparison of continuous
193 variables, while Chi-Square-Test/Fisher's test was used for categorial variables. All statistical analyses were
194 conducted using GraphPad PRISM 9.4.1 (GraphPad Software Inc., San Diego, CA, USA). A p-value <0.05 was
195 regarded as statistically significant.

196 **Illustrations**

197 Parts of Fig. 3 and 4 were drawn by using pictures from Servier Medical Art. Servier Medical Art by Servier is
198 licensed under a Creative Commons Attribution 3.0 Unported License
199 (<https://creativecommons.org/licenses/by/3.0/>).

200 **RESULTS**

201 **Diagnostic workup, clinical data and imaging results**

202 The diagnostic work-up of suspected PASC-ILD patients who presented to our outpatient clinic at the
203 Bundeswehrkrankenhaus (army hospital) Ulm in 11/2020-04/2021 is summarized in **Fig. 1 A**. **Tab. 1** summarizes
204 clinical and serological data of the PASC cohort who underwent transbronchial biopsy (n=51) and the
205 independent cohort of BAL samples for legendplex immunoassay (n=18). All patients were unvaccinated and
206 had not been hospitalized for COVID-19, 25/51 patients were soldiers (37.9%). Results from imaging were
207 heterogeneous with ground glass opacities (GGO) in 9/51 and reticulations in 3/51 pts (17.6% and 5.9%),
208 respectively (**Fig. 1 B**). Areas with low attenuation volume (LAV, below -950 HU) comprised more than 5% of
209 the lungs in 18/51 pts (35.3%), of which in 8/51 pts (15.7%) LAV areas comprised more than 10% of the lungs.
210 The most frequent pathological result from pulmonary function test were impaired MEF50 and FEV1 ($\leq 80\%$) in
211 42.9 and 16% of patients while median MEF50 and FEV1 throughout the cohort were 88 (IQR, 66-99) and 95.5
212 (IQR, 85-102), respectively. When correlating the results from lung function tests (**Tab. 1**) with clinical,
213 serological and imaging data, there was a significant association between time since infection and oxygen
214 pulse, but not residual volume (p<0.01 and p=0.1679, respectively) (**Fig. 1 C**). All other characteristics showed
215 no significant association. Autoantibodies (ANA titer $\geq 1:320$ and/or positive immunoblot for Scl-70, PCNA, PM-
216 Scl, dsDNA, SS-B, Histone) were detected in 17/51 pts (33.3%) but did not correlate with severity of symptoms
217 or specific imaging (GGO, reticulation) or histopathological characteristics (OP, inflammatory infiltrate,
218 evidence of fibrosis). **Fig. 1 D** summarizes results from lung function tests, imaging, serology, and tissue-based
219 SARS-CoV-2 detection (see below), stratified according to time since acute COVID-19.

220 **Histopathologic findings and tissue-based SARS-CoV-2 detection**

221 Histopathologic evaluation of transbronchial biopsies from PASC patients and lung tissue samples from pre-
222 pandemic autopsy controls ($n=15$, median age 56, 33% female) showed increased peribronchiolar and
223 interstitial lymphocytosis (see below for quantification and statistical evaluation) and alveolar fibrin deposition
224 in the PASC cohort (**Fig. 2 A** and **Tab. 2**). Organizing pneumonia was present in 2 PASC patients (3.9%) but not in
225 autopsy controls ($p>0.999$). Centrilobular lymphoid follicles were observed in 47% of PASC samples and 40% of
226 autopsy controls ($p=0.558$), while interstitial fibrosis (as assessed by Masson-Goldner staining and light
227 microscopy) was present in 27% of PASC patients and 13% of pre-pandemic autopsy controls ($p=0.3262$).
228 Immunohistochemistry for N and S proteins as well as RT-PCR for the RdRp gene of SARS-CoV-2 was negative in
229 all tissue samples but one case was positive for E gene in RT-PCR (**Fig. 1 D**) and confirmed by SARS-CoV-2 S FISH
230 analysis of the alveolar epithelium (**Fig. 2 B**).

231 **Spatial T lymphocyte subtyping in PASC patients and autopsy controls.**

232 The inflammatory infiltrates around small airways and in alveolar septa consisted of CD3+ T cells, with a
233 predominance of CD4+ over CD8+ T cells (**Fig. 3 A**). CD4+ T cells around small airways were significantly
234 increased compared to the interstitium in PASC patients ($p=0.0205$) as well as compared to both airways and
235 interstitium of autopsy controls ($p=0.0154$ and $p<0.0001$, respectively) (**Fig. 3 B** and **Tab. 2**). There was no such
236 difference in the distribution of CD8+ T cells between airways and interstitium as well as between PASC
237 patients and autopsy controls (**Fig. 3 B** and **Tab. 2**). The CD4/CD8 ratio was not significantly different between
238 BAL fluid and tissue samples (small airways and interstitium) from PASC patients or autopsy controls. When
239 analyzing the spatial distribution of the inflammatory infiltrate in PASC patients, there was consistently more
240 inflammation around the airways compared to the interstitium, but no significant difference between CD4+ or
241 CD8+ T cell density between airways or interstitium of the middle and lower lobe, respectively (**Fig. 3 C**). While
242 there was a negative correlation between time since COVID-19 and airway T cell infiltrate, this trend was not
243 statistically significant ($p=0.1736$).

244 **Assessment of interstitial fibrosis and quantification of macrophage subpopulations in PASC patients.**

245 Ultrastructural analysis (TEM) was performed on 11 of 14 PASC lung tissue samples with evidence of fibrosis in
246 light microscopy and showed interstitial deposition of collagen fibrils in all cases (**Fig. 4 A** and **Tab. 2**).
247 Immunofluorescence multiplex staining of lung tissue samples ($n=38$) for the quantification of macrophage
248 subpopulations (**Fig. 4 B**) showed no significant differences between H-scores for pro-fibrotic macrophage
249 phenotype (CD68/CD163/S100A9) according to clinical, imaging or serological data including diffusion capacity
250 for carbon monoxide, oxygen pulse or number of CD4+/CD8+ T cells around airways or in alveolar septa (**Fig. 4**
251 **C** and **D**). The results from immunofluorescence multiplex staining are summarized in **Tab. 3**. The median
252 proportion of CD163+ Macrophages among all Macrophages was 32%. Although this is higher than the median
253 proportion of CD163+ Macrophages in a previously published control cohort (12%)[16], the difference was not
254 statistically significant ($p=0.2792$). Analysis of cytokines in BAL fluid using legendplex immunoassay showed
255 elevated levels of IL-1beta ($p<0.05$) and IL-8 compared to healthy controls, although the latter increase was not
256 statistically significant (**Fig. 4 E**).

257

258

259

260 **DISCUSSION**

261 In the present study, we report on the histopathological, serological, clinical and imaging characteristics in a
262 consecutive cohort of 51 patients from the postCOVID outpatient clinic of the Bundeswehrkrankenhaus (army
263 hospital) Ulm.

264 In comparison to most published data on the epidemiology of PASC [17], our patient cohort was younger
265 (median age, 40 years) and the male sex was predominant (57%), both possibly due to the high proportion of
266 active soldiers in the study and reflecting data from other studies involving military personnel [18].

267 Although all patients presented with dyspnea on exertion, pulmonary function tests revealed only limited
268 pathological results. The most relevant finding were reduced MEF 50 and FEV1 ($\leq 80\%$) in 42.9 and 16% of
269 patients, in line with results from a previous study on athletes [19]. Airflow obstruction with a resulting
270 reduction in MEF50/ FEV1 would be plausible concerning the observed proportion of patients with LAV $>5\%$ or
271 $>10\%$ of lung area and the histopathologic finding of T cell-mediated bronchiolitis. It has been suggested that
272 spiroergometry should be performed to assess cardiopulmonary function in PASC patients [20], but the median
273 oxygen pulse was in the normal range. Since we had no pre-infection data, the actual impact of SARS-CoV-2
274 infection on individual cardiopulmonary function could not be assessed. Our data is in contrast to a study from
275 Finland which did not find evidence of small airway inflammation in survivors of severe COVID-19 [21]. This
276 difference might be due to the fact that we investigated a preselected cohort of patients with pulmonary
277 symptoms after mild course of the disease who had not previously undergone anti-inflammatory treatment for
278 severe COVID-19.

279 The observed correlation between oxygen pulse and time since infection in the complete cohort points towards
280 normalization of oxygen pulse over time, possibly due to the parallel decrease in airway inflammation. In line
281 with previous data [22], imaging in PASC patients showed GGOs and reticulations. There was no specific
282 radiologic feature associated with clinical data, results from pulmonary function test or histopathological
283 findings. In line with our finding of reduced MEF50/FEV1 in a subset of patients and our hypothesis of
284 bronchiolitis-derived airflow obstruction, 35.3% of patients showed low attenuation volume (LAV) in $>5\%$ of
285 lung area.

286 Both autoimmunity and persistence of virus/viral particles are discussed as possible contributors in the
287 pathophysiology of PASC [11,13]. Using immunohistochemistry and RT-PCR, we did not detect SARS-CoV-2 or
288 virus-derived spike or nucleocapsid proteins in lung tissue samples from all but one (2%) of PASC patients. In
289 this patient the presence of SARS-CoV-2 could be confirmed by FISH in alveolar epithelium at 35 weeks after
290 infection. Since this is a much longer time span than has previously been reported [23], it might be possible
291 that the patient had a recent reinfection with SARS-CoV-2 despite negative RT-PCR from nasopharyngeal swab
292 prior to inclusion into the present study.

293 We conclude that in the lung, persistence of virus/viral particles is not necessary for ongoing peribronchiolitis.
294 This parallels the situation in acute COVID-19, where organization of diffuse alveolar damage/acute lung injury
295 and long-term outcomes, such as pulmonary fibrosis occur after viral clearance and are therefore independent

296 from the presence of virus [15]. With respect to autoantibodies, 33.3% of patients in the present study had
297 detectable autoantibodies (ANA/ENA). Presence of autoantibodies was not associated with specific clinical
298 characteristics, results from pulmonary function test or histopathological findings. Thus, they might reflect
299 extrafollicular B cell activation upon contact with SARS-CoV-2 [24].
300 Histopathologic features of PASC were mostly discrete and non-specific, such as alveolar fibrin deposition and
301 organizing pneumonia. When compared with pre-pandemic autopsy controls, there was significantly increased
302 CD4+ (but not CD8+) T cell infiltrate around small airways (bronchiolitis), while interstitial CD4+/CD8+ T cell
303 infiltrates were not significantly different. According to the classification proposed by Ryu [25], the
304 inflammation pattern and imaging results reflected primary bronchiolitis rather than interstitial lung diseases
305 with a prominent bronchiolar component. Previous viral or mycoplasmic infections are a frequent cause of
306 primary bronchiolitis in children and adults and it has been shown that CD4+ T cells play a major role in
307 obliterative bronchiolitis in chronic lung allograft dysfunction (CLAD) [26,27]. Bronchiolitis might also contribute
308 to airflow obstruction that would explain the observed decrease in MEF50/FEV1 and increase of LAV areas in a
309 subset of patients. Given 1) the established correlation between viral infections and persistent airway
310 inflammation and 2) the absence of detectable SARS-CoV-2 in all but one patient, bronchiolitis in PASC seems
311 to represent a rather unspecific post-infection reaction. Small peribronchiolar lymphoid follicles were present
312 in about half of the patients. However, since interstitial inflammation was sparse, we would not see fulfilment
313 of diagnostic criteria for IPAF/CTD-ILD that have previously been proposed [28,29]. It has to be noted, however,
314 that no surgical lung biopsies were performed that would have allowed for recognition of cellular or fibrotic
315 NSIP patterns in support of a diagnosis of IPAF/CTD-ILD. Finally, in a subset of patients, fibrotic remodeling
316 could be detected by light microscopy and confirmed by TEM analysis; cytokine profiling of BAL fluid in an
317 independent PASC cohort showed elevated levels of IF-1 β . The proportion of CD163+ macrophage
318 subpopulation in PASC lung tissue samples was higher than in a previously published control cohort, but this
319 result was not statistically significant and the density of pro-fibrotic macrophages did not correlate with
320 presence of fibrosis, clinical or imaging characteristics or the detection of autoantibodies. Still, we feel that
321 pulmonary function should be monitored closely in PASC patients to allow for early detection and treatment of
322 possible pulmonary fibrosis since it has been previously shown that SARS-CoV-2 has the ability to induce lung
323 fibrosis [30,15].
324 There are several limitations to our study. First, we only included patients from a single center who had actively
325 sought diagnostics and treatment of pulmonary symptoms after mild COVID-19, so it is impossible to draw any
326 conclusions about the frequency and severity of pulmonary PASC in the general population. Second, the
327 significance of the findings for an individual patient might be limited due the high number of physically active
328 soldiers in our cohort who might have less tolerance for even slight impairment of lung function. On the other
329 hand, the absence of relevant pulmonary comorbidities in this particular group and the fact that infections
330 occurred before the widespread roll-out of vaccines offered a unique opportunity to study the natural course
331 of lung pathology after SARS-CoV-2 infection. Third, since most patients were infected during the alpha/delta
332 waves, it is unclear whether the findings hold true for infections with omicron or other subtypes of SARS-CoV-2.
333 Finally, inclusion of lung tissue samples from patients after non-COVID viral infections as controls would have
334 allowed us to investigate to which extent post-infection bronchiolitis/fibrosis is COVID-specific, however these

335 patients do not usually undergo biopsy. We will follow-up the present cohort to investigate whether
336 bronchiolitis and autoantibodies persist and to monitor whether there is clinical evidence of progressive
337 fibrosis especially in the subset of patients who had first evidence of fibrosis in the baseline biopsy.

338 **SUMMARY AND INTERPRETATION**

339 We report here on a consecutive cohort of 51 unvaccinated patients who presented with pulmonary PASC,
340 mostly in form of dyspnea on exertion. Only a minority of these patients had significantly impaired lung
341 function, however a significant subset had impaired MEF50/FEV1 and enhanced LAV, in line with airflow
342 obstruction, possibly due to T cell-mediated bronchiolitis. Residual SARS-CoV-2 was not detectable in lung
343 tissue of all but one PASC patient, but a subset of patients showed evidence of fibrotic remodeling of the lung.
344 We think that obstructive lung disease due to post-infectious bronchiolitis without viral persistence is the main
345 cause of pulmonary PASC after mild course of the disease. While in most cases pulmonary symptoms might be
346 self-limiting and wane over time, there is evidence of early fibrotic remodeling in a subset of PASC patients.

347

348 **ACKNOWLEDGEMENTS**

349 The authors would like to thank all patients for their consent to the use of data and images in the present
350 study.

351

352 **AUTHOR CONTRIBUTIONS**

353 Study concept: DG, WB, PB and KS. Data collection: DG, CH, AC, AL, NM, WB, FZ, FK, SD, SvS, RB, PB, KS. Sample
354 collection: DG, NM, SvS, KS. Initial draft of manuscript: KS. Critical revision and approval of final version: all
355 authors.

356

357 **REFERENCES**

- 358 1. Xie Y, Bowe B, Al-Aly Z (2021) Burdens of post-acute sequelae of COVID-19 by severity of acute
359 infection, demographics and health status. *Nature communications* 12 (1):1-12
- 360 2. Lerner AM, Robinson DA, Yang L, Williams CF, Newman LM, Breen JJ, Eisinger RW, Schneider JS,
361 Adimora AA, Erbelding EJ (2021) Toward understanding COVID-19 recovery: National Institutes of
362 Health workshop on postacute COVID-19. *Annals of internal medicine* 174 (7):999-1003
- 363 3. Havervall S, Rosell A, Phillipson M, Mangsbo SM, Nilsson P, Hober S, Thålin C (2021) Symptoms and
364 functional impairment assessed 8 months after mild COVID-19 among health care workers. *Jama* 325
365 (19):2015-2016
- 366 4. Solomon JJ, Heyman B, Ko JP, Condos R, Lynch DA (2021) CT of postacute lung complications of
367 COVID-19. *Radiology*
- 368 5. Torres-Castro R, Vasconcello-Castillo L, Alsina-Restoy X, Solís-Navarro L, Burgos F, Puppo H, Vilaro J
369 (2021) Respiratory function in patients post-infection by COVID-19: a systematic review and meta-
370 analysis. *Pulmonology* 27 (4):328-337
- 371 6. Chun HJ, Coutavas E, Pine AB, Lee AI, Vanessa LY, Shallow MK, Giovacchini CX, Mathews AM,
372 Stephenson B, Que LG (2021) Immunofibrotic drivers of impaired lung function in postacute sequelae
373 of SARS-CoV-2 infection. *JCI insight* 6 (14)
- 374 7. Diaz A, Bujnowski D, McMullen P, Lysandrou M, Ananthanarayanan V, Husain AN, Freeman R,
375 Vigneswaran WT, Ferguson MK, Donington JS (2022) Pulmonary parenchymal changes in COVID-19
376 survivors. *The Annals of Thoracic Surgery* 114 (1):301-310

- 377 8. Haslbauer JD, Bratic-Hench I, Cima K, Luger AK, Schmitz K, Augustin F, Krapf C, Hoefer D, Tancevski
378 I, Tzankov A (2022) Interstitial Pulmonary Fibrosis and Extensive Dendriform Ossification with
379 Persistent Viral Load: A Rare Presentation of Post-COVID-19 Condition in Need of Lung
380 Transplantation. *Pathobiology*:1-8
- 381 9. Cheon I, Li C, Son Y, Goplen N, Wu Y, Cassmann T, Wang Z, Wei X, Tang J, Li Y (2021) Immune
382 signatures underlying post-acute COVID-19 lung sequelae. *Science Immunology* 6 (65):eabk1741
- 383 10. Dhawan RT, Gopalan D, Howard L, Vicente A, Park M, Manalan K, Wallner I, Marsden P, Dave S,
384 Branley H (2021) Beyond the clot: perfusion imaging of the pulmonary vasculature after COVID-19.
385 *The Lancet Respiratory Medicine* 9 (1):107-116
- 386 11. Son K, Jamil R, Chowdhury A, Mukherjee M, Venegas C, Miyasaki K, Zhang K, Patel Z, Salter B,
387 Yuen ACY (2022) Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID
388 symptoms. *European Respiratory Journal*
- 389 12. Gagiannis D, Steinestel J, Hackenbroch C, Schreiner B, Hannemann M, Bloch W, Umathum VG,
390 Gebauer N, Rother C, Stahl M (2020) Clinical, Serological, and Histopathological Similarities Between
391 Severe COVID-19 and Acute Exacerbation of Connective Tissue Disease-Associated Interstitial Lung
392 Disease (CTD-ILD). *Frontiers in immunology* 11:2600
- 393 13. Merad M, Blish CA, Sallusto F, Iwasaki A (2022) The immunology and immunopathology of COVID-
394 19. *Science* 375 (6585):1122-1127
- 395 14. Garcia GL, Valenzuela A, Manzoni T, Vaughan AE, López CB (2020) Distinct chronic post-viral lung
396 diseases upon infection with influenza or parainfluenza viruses differentially impact superinfection
397 outcome. *The American Journal of Pathology* 190 (3):543-553
- 398 15. Gagiannis D, Umathum VG, Bloch W, Rother C, Stahl M, Witte HM, Djudjaj S, Boor P, Steinestel K
399 (2022) Antemortem vs postmortem histopathologic and ultrastructural findings in paired
400 transbronchial biopsy specimens and lung autopsy samples from three patients with confirmed SARS-
401 CoV-2. *American Journal of Clinical Pathology* 157 (1):54-63
- 402 16. Wendisch D, Dietrich O, Mari T, von Stillfried S, Ibarra IL, Mittermaier M, Mache C, Chua RL, Knoll
403 R, Timm S (2021) SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis.
404 *Cell* 184 (26):6243-6261. e6227
- 405 17. Fumagalli C, Zocchi C, Tassetti L, Silverii MV, Amato C, Livi L, Giovannoni L, Verrillo F, Bartoloni A,
406 Marcucci R (2022) Factors associated with persistence of symptoms 1 year after COVID-19: A
407 longitudinal, prospective phone-based interview follow-up cohort study. *European Journal of Internal
408 Medicine* 97:36-41
- 409 18. Adam T, Sammito S, Nicol E, Guettler N (2022) Return to flying duties of German military pilots
410 after recovery from COVID-19. *BMJ Mil Health*
- 411 19. Komici K, Bianco A, Perrotta F, Dello Iacono A, Bencivenga L, D'Agnano V, Rocca A, Bianco A,
412 Rengo G, Guerra G (2021) Clinical characteristics, exercise capacity and pulmonary function in post-
413 COVID-19 competitive athletes. *Journal of Clinical Medicine* 10 (14):3053
- 414 20. Fikenzer S, Kogel A, Pietsch C, Lavall D, Stöbe S, Rudolph U, Laufs U, Hepp P, Hagendorff A (2021)
415 SARS-CoV2 infection: functional and morphological cardiopulmonary changes in elite handball
416 players. *Scientific Reports* 11 (1):1-9
- 417 21. Lindahl A, Reijula J, Malmberg LP, Aro M, Vasankari T, Mäkelä MJ (2021) Small airway function in
418 Finnish COVID-19 survivors. *Respiratory research* 22 (1):1-5
- 419 22. Vijayakumar B, Tonkin J, Devaraj A, Philip KE, Orton CM, Desai SR, Shah PL (2022) CT lung
420 abnormalities after COVID-19 at 3 months and 1 year after hospital discharge. *Radiology* 303 (2):444
- 421 23. Corcoran MA, Olin S, Rani G, Nasenbeny K, Constantino-Shor C, Holmes C, Quinnan-Hostein L,
422 Solan W, Newman GS, Roxby AC (2021) Prolonged persistence of PCR-detectable virus during an
423 outbreak of SARS-CoV-2 in an inpatient geriatric psychiatry unit in King County, Washington.
424 *American journal of infection control* 49 (3):293-298
- 425 24. Woodruff MC, Bonham KS, Anam FA, Walker TA, Ishii Y, Kaminski CY, Ruunstrom MC, Truong AD,
426 Dixit AN, Han JE, Ramonell RP, Haddad NS, Rudolph ME, Jenks SA, Khosroshahi A, Lee FE-H, Sanz I
427 (2022) Inflammation and autoreactivity define a discrete subset of patients with post-acute sequelae
428 of COVID-19, or long-COVID. *medRxiv*:2021.2009.2021.21263845. doi:10.1101/2021.09.21.21263845

- 429 25. Ryu JH (2006) Classification and approach to bronchiolar diseases. Current opinion in pulmonary
430 medicine 12 (2):145-151
- 431 26. Fischer GB, Sarria EE, Mattiello R, Mocelin HT, Castro-Rodriguez JA (2010) Post infectious
432 bronchiolitis obliterans in children. Paediatric respiratory reviews 11 (4):233-239
- 433 27. Wu Q, Gupta PK, Suzuki H, Wagner SR, Zhang C, Cummings OW, Fan L, Kaplan MH, Wilkes DS,
434 Shilling RA (2015) CD4 T cells but not Th17 cells are required for mouse lung transplant obliterative
435 bronchiolitis. American Journal of Transplantation 15 (7):1793-1804
- 436 28. Suda T, Kono M, Nakamura Y, Enomoto N, Kaida Y, Fujisawa T, Imokawa S, Yasuda K, Hashizume
437 H, Yokomura K (2010) Distinct prognosis of idiopathic nonspecific interstitial pneumonia (NSIP)
438 fulfilling criteria for undifferentiated connective tissue disease (UCTD). Respiratory medicine 104
439 (10):1527-1534
- 440 29. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK,
441 Morell F (2018) Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical
442 practice guideline. American journal of respiratory and critical care medicine 198 (5):e44-e68
- 443 30. Kamp JC, Neubert L, Ackermann M, Stark H, Werlein C, Fuge J, Haverich A, Tzankov A, Steinestel
444 K, Friemann J (2022) Time-dependent molecular motifs of pulmonary fibrogenesis in COVID-19.
445 International Journal of Molecular Sciences 23 (3):1583

446

447 **FIGURE LEGENDS**

448 **Figure 1. Characterization and diagnostic work-up of PASC patients.** **A**, Flow diagram for diagnostic
449 work-up of suspected PASC-ILD patients. Lung biopsies from 51 PASC patients were finally included in
450 histopathological assessment. **B**, representative imaging of acute COVID-19 (left) and PASC (right)
451 with discrete reticulation and ground glass opacities (arrowheads, 9 months post-infection). **C**,
452 correlation between oxygen pulse (left, $p<0.01$) and residual volume (right, $p=0.1679$) and time since
453 COVID-19, indicating restoration of lung function over time. **D**, heatmap stratified according to time
454 post infection (2 wks to 55 wks) displaying the results from lung function tests, imaging,
455 autoantibody screening and tissue-based SARS-CoV-2 detection. FISH analysis was only performed in
456 the single patient with positive SARS-CoV-2 RT-PCR (case #41).

457 **Figure 2. Histology and tissue-based SARS-CoV-2 detection.** **A**, Representative microphotographs of
458 H.E.-stained lung tissue samples from PASC patients showing organizing pneumonia (arrowhead),
459 alveolar fibrinous exudate (arrows) and interstitial lymphocytosis (right image). Masson-Goldner
460 staining showing minimal interstitial fibrosis. **B**, Representative microphotographs of
461 immunohistochemistry for SARS-CoV-2 Spike (S) and Nucleocapsid (N) proteins in airways and lung
462 alveoli in acute COVID-19 (upper panel) and PASC (lower panel). Both IHC stainings were negative in
463 all PASC cases. SARS-CoV-2 S FISH showed sparse signals in alveolar epithelium the single patient
464 with positive SARS-CoV-2 RT-PCR (case #41). *Scale bar, 100μm.*

465 **Figure 3. Spatial T lymphocyte subtyping in PASC patients.** **A**, representative microphotographs of
466 immunohistochemistry for pan-T-cell-marker (CD3) and CD4/CD8 double-staining in small airways
467 (triangle) and lung alveoli (circle). **B**, statistical analyses showed significantly elevated numbers of
468 CD3+ T-cells and CD4+ T-helper cells, but not CD8+ cytotoxic T-cells, in small airways compared to
469 interstitium in PASC patients as well as compared to both small airways and interstitium of pre-
470 pandemic autopsy controls. CD4/CD8 ratio was not significantly different compared to both PASC
471 BAL fluid and pre-pandemic autopsy controls. **C**, distribution of CD4+/CD8+ T-cells between different
472 biopsy sites (middle lobe/lower lobe) and correlation between T-cell infiltration and time since
473 COVID-19. There was a decrease in the number of airway T-cells over time.

474 **Figure 4. Assessment of interstitial fibrosis and quantification of macrophage subpopulations in**
475 **PASC patients. A,** TEM shows interstitial deposition of collagen fibrils. **B,** representative
476 microphotographs of immunofluorescence multiplex staining of lung tissue samples. *Scale bar,*
477 $100\mu\text{m}$. **C,** H-scores for pro-fibrotic macrophage phenotype (CD68/CD163/S100A9) were not
478 significantly different between men and women or between biopsy site (middle lobe vs. lower lobe).
479 There was no significant correlation between H-scores for pro-fibrotic macrophage phenotype and
480 between lymphocyte count in BAL, diffusion capacity for carbon monoxide or oxygen pulse. **D,** no
481 significant correlation between H-scores for pro-fibrotic macrophage phenotype and CD3+ T-cells/
482 CD4+ T-helper cells/ CD8+ cytotoxic T-cells in both small airways and interstitium. **E,** legendplex
483 immunoassay from BAL fluid shows elevated levels of IL-1 β ($p<0.05$) and IL-8 compared to healthy
484 controls, although the latter result did not turn out statistically significant.

485

Table 1. Baseline clinical characteristics and assessment of lung function in PASC patients.

Characteristics	PASC patients (tissue cohort) (n = 51)	PASC patients (BAL cohort) (n=18)	p-value
Age (years; median, range)	40 (18 - 80)	46 (20-82)	0.4742
Gender (%)			
Female	22 (43)	7 (39)	
Male	29 (57)	11 (61)	0.7889
Weeks since SARS-CoV-2 (median, range)	17 (2-55)	22 (12-108)	0.0052
Presence of autoantibodies ¹ (n, %)	17 (33.3)	7 (38.9)	0.7754
FVC, % pred (median, IQR)	94 (87-102)	90 (37-110)	0.0201
TLC, % pred (median, IQR) (n=50)	102.5 (93-111)	97 (54-149)	0.4343
FEV1, % pred (median, IQR) (n=50)	95.5 (85-102)	89.5 (44-105)	0.0229
MEF50, % pred (median, IQR)(n=42)	88 (66-99)	77.5 (70-97)	0.5387
D _{LCO} , % pred (median, IQR) (n=49)	94 (87-113)	87 (43-132)	0.0798
VO2/HF (median, IQR)(n=29)	13.5 (10-15)	10.5 (7.2-19)	0.2776
Low FVC <80% pred, n (%)	5 (9.8)	4 (22.2)	0.2259
Low TLC <80% pred, n (%)	3 (6)	3 (16.7)	0.3296
Low FEV1 <80% pred, n (%)	8 (16)	3 (16.7)	>0.9999
Low MEF50 <80% pred, n (%)	17 (42.9)	10 (55.5)	0.3967
Low D _{LCO} <70% pred, n (%)	2 (4.1)	3 (16.7)	0.1072
LAV >5%, n (%)	18 (35.3)	n.a.	n.a.
BAL			
Lymphocyte count (median, IQR)	13 (8-20)	12 (7-27)	0.6312
CD4/CD8 ratio (median, IQR)	2.2 (1.6-3.2)	3.2 (0.95-5.8)	0.2782

¹ANA titer ≥ 1:320 and/or positive IB (Scl-70, PCNA, PM-Scl, dsDNA, SS-B, Histone) or RF > 20 U/ml; FVC: forced vital capacity; IQR, interquartile range; TLC: total lung capacity; FEV1: forced expiratory volume in 1 s; MEF50: mean expiratory flow at 50% of FVC; D_{LCO}: diffusing capacity of the lung for carbon monoxide; VO2/HF: oxygen pulse; LAV, low attenuation volume; BAL: broncho-alveolar lavage.

Table 2. Lung histology and spatial T lymphocyte subtyping in post-COVID patients and pre-pandemic autopsy controls.

Characteristics	PASC (n = 51)	Autopsy controls (n=15)	p-value
Age (years; median, range)	40 (18 - 80)	56 (25-82)	0.0006
Gender			
Female	22 (43%)	5 (33%)	0.5627
Male	29 (57%)	10 (67%)	
Organizing pneumonia			
present	2 (4%)	0	>0.999
absent	49 (96%)	15 (100%)	
Lymphoid follicles			
present	24 (47%)	6 (40%)	0.5580
absent	27 (53%)	9 (60%)	
Interstitial fibrosis			
Light microscopy, n (%)	14/51 (27%)	2 (13%)	0.3262
TEM, n (%)	11/11 (100%)	n. a.	
Small airways (bronchi/bronchioles) (n=35)			
CD4+ cells/0.1 mm ² (IQR)	6.7 (4-8)	3.7 (3-5)	0.0154
CD8+ cells/0.1 mm ² (IQR)	4.2 (1-6)	2.4 (1-4)	0.1327
CD4/CD8 ratio (IQR)	2.6 (1.2-12)	2 (1-5)	0.8487
Interstitialium (alveolar septae) (n=35)			
CD4+ cells/0.1 mm ² (IQR)	4.6 (3-5.5)	2.2 (1-3)	0.067
CD8+ cells/0.1 mm ² (IQR)	2.8 (1-4)	2.2 (1-3)	0.8794
CD4/CD8 ratio (IQR)	2.4 (1.3-8)	1.3 (1-2)	0.2626

Table 3. Macrophage panel staining and automated quantitative imaging.

Characteristics	PASC (n = 38)
Age (years; median, range)	39.5 (18 - 82)
Gender	
Female	23 (44%)
Male	29 (56%)
Cells/mm ² (median, IQR)	
CD 68+	26 (14-46)
CD 16+	116 (17-539)
CD 16+/CD163+	151 (72-258)
CD 68+/CD163+	6 (1-77)
CD163+ Macrophages/all Macrophages (median, IQR)	0.32 (0.15-0.79)
H-scores	
S100A9+ (other cells)	6 (2-22)
CD 68+/S100A9+	2 (0-9)
CD 16+/S100A9+	39 (13-61)
CD 16+/CD163+/S100A9+	221 (123-252)
CD 68+/CD163+/S100A9+	34 (0-85)

Figure 1








Figure 2

A



B






Figure 3

A



B



C








Figure 4**A****B****CD16 / CD68 / CD163 / S100A9****C****D****E**